Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Back in the 1950s, researchers in the food and pharmaceutical sectors started searching for stable alternatives to natural resins and gums. That search led chemists towards sucrose derivatives, driven by the recognition that sugar-based compounds offered both safety and versatility. Sucrose Acetate Isobutyrate (SAIB) emerged through this focus. Companies developed it to stabilize flavor oils in beverages, avoiding typical issues caused by natural gums, like unpredictable reactions or supply fluctuations. Over time, SAIB’s reputation for safety caught the attention of regulatory agencies, and it earned approvals across regions including Europe, the US, and Asia. Pharmaceutical manufacturers soon adopted it for its consistency and compatibility with drug formulations.
Sucrose Acetate Isobutyrate appears as a thick, nearly colorless to pale yellow syrup. In pharma circles, it stands out for superb solubility in various organic solvents and its chemically inert nature. Compared to other excipients, SAIB supports both solubilization and stability, without bringing strong odors or tastes that could interfere with delicate formulations. Its popularity grew from these strengths, quickly becoming a staple in oral suspensions and certain topical applications. Pharma grade SAIB undergoes strict filtration and purification, ensuring the removal of by-products to meet EP, BP, and USP standards.
SAIB’s viscosity makes it easy to manage during production and blending. It remains stable through a wide temperature range, showing resistance to oxidation and hydrolysis. The molecule itself is a complex ester, built from sucrose, acetic acid, and isobutyric acid. Water doesn’t dissolve it, but a range of organic solvents do—ethyl acetate, ethanol, and some oils. Its specific gravity hovers near 1.15 at room temperature. Chemists appreciate the slow movement of this liquid, as it prevents unwanted sedimentation in suspensions and controls the migration of flavors or actives within solutions. For the exacting requirements of BP, EP, and USP, manufacturers guarantee low levels of impurities like free acids and unreacted sugars, which can impact both stability and safety.
Suppliers provide extensive documentation alongside each batch. Labels offer more than just the product name, listing full chemical structure, batch codes, date of manufacture, expiry date, and precise assay values—usually noting a purity above 98%. They also provide details on acid and water content, residual solvents, and any stabilizers included during production. Storage recommendations feature prominently, since prolonged exposure to moisture or high temperatures can raise the risk of degradation. Pharmaceutical-grade suppliers include certificates of analysis with every lot, showing compliance with all relevant pharmacopoeia monographs.
To create Sucrose Acetate Isobutyrate at significant scale, manufacturers begin with fully refined sucrose, reacting it in steps with acetic anhydride and isobutyric anhydride, usually in the presence of approved catalysts. Temperature and agitation get tightly controlled to avoid side reactions. Once the reaction completes, chemists remove excess reagents and by-products through successive washes, filtration, and sometimes vacuum distillation. These steps keep impurity levels within pharmacopeial specifications. The result—a heavy, clear syrup—gets stored in light-resistant, airtight containers prior to packaging and distribution.
SAIB’s core strength comes from its stable ester bonds, which resist breakdown even under stress. Little chemical reactivity exists, making it safe as a carrier or suspending agent for sensitive drugs or actives. Some R&D teams explore partial hydrolysis in the laboratory, looking to increase aqueous dispersibility for niche pharma formulations. Chemical modifications rarely see commercial scale, due to the balance between stability and function present in the standard product. Still, the field is far from static: academic papers explore introducing functional groups to the sucrose core, aiming to add new release profiles or cross-linking capabilities, though such modifications often run into safety barriers.
On shipping containers and regulatory filings, the compound often appears as ‘SAIB’, ‘Sucrose acetate isobutyrate’, and less often as ‘E444’ in food-related contexts. Other names include ‘Sucrose, acetate, isobutyrate’ and ‘Sucrose mixed ester of acetic and isobutyric acids’. Exact names differ by region, but suppliers always link to the compound’s CAS number (27216-37-1) for regulatory clarity. Pharma grade sources distinguish their product with added documentation attesting to compliance with BP, EP, and USP.
Any excipient used in pharmaceuticals receives heavy regulatory scrutiny. Long experience with SAIB shows low toxicity in mammals, both orally and by other exposure routes. The US FDA lists Sucrose Acetate Isobutyrate as Generally Recognized as Safe (GRAS) for food, and pharmacopoeias set purity standards that include heavy metal and residual solvent limits. Handling guidelines mirror those for thick, non-reactive liquids—gloves, goggles, and local exhaust when pouring or mixing. Spills rarely cause major harm but can create slippery surfaces. SAIB lacks volatility or reactivity, so facilities rarely struggle with complex environmental containment or special firefighting measures. Waste disposal involves careful collection, avoiding dilution into waterways, since high concentrations can influence local microbial activity.
Pharmaceutical scientists value SAIB for its role as a suspending agent and carrier in both oral and topical medicines. In liquid medicines—especially suspensions—it holds drugs or flavors evenly distributed for stable dosing. Many cough syrups, pediatric vitamins, and topical sprays count on SAIB’s film-forming qualities. In more advanced drug delivery, innovators add SAIB to modify release rates of active ingredients, especially in sticky, slow-release patches and sprays. The food industry takes advantage of its emulsifying strengths to keep oils mixed in soft drinks. Cosmetics chemists draw on its film-forming traits for hair sprays and skin products. This wide use reflects SAIB’s chemical reliability and the large safety data set supporting it.
Ongoing research targets specialized esters of sucrose, aiming to adapt them for tougher regulatory expectations and new routes of drug delivery. Current studies examine whether tweaking the acetyl or isobutyryl ratios improves solubility or bioavailability for oral and transmucosal medications. Innovators are also testing SAIB as a matrix for nanoparticle drugs, since its slow diffusion and low water solubility can stabilize actives that break down in aqueous environments. Researchers examine how SAIB influences release rates, drug stability, and sensory perception. These efforts often move from bench-scale synthesis to preclinical trials, with safety as a constant hurdle for regulatory teams. The data generated continues to expand the case for SAIB in complex, next-generation pharma products, especially those that demand high stability and predictable release in the human body.
Extensive animal studies demonstrate that SAIB does not produce serious adverse effects at doses much higher than any found in medicine or food. Short-term tests show no irritation or allergic reactions when applied to skin or mucosa. Even large, repeated oral doses failed to induce toxicity or affect reproductive health in rat and mouse models. Chronic exposure studies in primates and dogs underline this safety, though vigilant researchers regularly re-examine this evidence as part of regulatory updates and new application reviews. Human exposure studies, though less comprehensive due to ethical limits, back up these findings—SAIB passes through the gut unchanged, showing almost no systemic absorption or metabolic alteration.
Excipient innovation often moves slowly, yet shifts in how drugs are delivered—such as through nanoemulsions, slow-release patches, and combination therapies—open fresh doors for classic compounds like SAIB. Formulators look to this molecule for answers in stabilizing medicines where water activity must stay low or ingredient separation threatens shelf life. Growing interest in personalized medicine puts renewed focus on excipients that support accurate dosing, long-term stability, and easy blending with delicate actives. As regulators keep raising the bar on impurity limits and processing transparency, manufacturers develop refining steps to produce even purer lots of SAIB, fully traceable from raw sugar to finished pharma product. Environmental sustainability also drives some future research, since greener production methods and better disposal options can strengthen the compound’s long-term appeal.
Sucrose Acetate Isobutyrate, often called SAI, doesn’t grab the headlines like other pharmaceutical ingredients, but it works hard behind the scenes. This compound shows up in medicines, drinks, and even personal care products. I’ve seen it take on several roles, from stabilizing flavors to improving medication delivery.
One of the most common jobs for SAI in the pharma world involves keeping oily medicines from separating inside a bottle. Picture a suspension or emulsion—years ago, those mixtures would often separate, giving you uneven doses. SAI acts like a stabilizer. It helps keep everything evenly mixed, so each dose stays consistent. That means you don’t end up swallowing pure oil or getting shortchanged on the main ingredient.
In cough syrups, for example, SAI helps keep oil-based flavors and active ingredients suspended. I’ve worked in pharmacies where separated medicines led to headaches for patients and staff. With SAI in the mix, folks don’t have to worry about shaking a bottle for five minutes before every use. The solution pours the same way every time, making medicine safer and easier for everyone involved.
People rarely mention how unpleasant some liquid medications taste. SAI plays a quiet role in helping flavors stick around longer and carry well through a whole bottle. This kind of stability can make the difference between a child taking their medicine willingly or refusing it. SAI’s tough structure protects flavors and colors from breaking down over time, even when stored for months.
Surprisingly, regulations have a big say here. The pharma-grade SAI has to meet strict BP, EP, and USP standards. These benchmarks keep quality high and contaminants low. Every lot faces tests for purity and consistency, making sure what ends up in a child’s spoon at home matches what the doctor prescribed.
Manufacturers favor SAI because its chemical makeup resists breaking down in water. This unique property allows SAI to keep water and oil from parting ways, like a really strong handshake between two old rivals. At low doses, SAI doesn’t mess with the texture or leave a weird taste, which can’t be said for every stabilizer on the market. It remains in the background, doing its job without drawing attention.
There’s always room for better transparency. SAI might trip up patients reading a label—they deserve to know why this compound is there. We need clearer communication between manufacturers and healthcare providers. Pharmacies can post up simple explanations about common ingredients like SAI, helping people feel more confident about what they’re taking.
Researchers seek alternatives and upgrades to SAI every year. While SAI does a reliable job, more natural or biodegradable options stand to offer even better safety profiles. Science marches forward, but every new ingredient has to prove it can do the heavy lifting as well as SAI currently does.
SAI keeps lives running smoother—from medication consistency to easier dosing for patients of all ages. Understanding what’s inside a medicine bottle gives us more trust in how we care for ourselves and our loved ones. For now, SAI still earns its place on the list of pharmaceutical helpers, holding medicines together and making healthcare just a bit easier.
Every pharmacist, chemist, or operator who’s ever handled excipients knows that a little impurity can lead to big headaches. Sucrose acetate isobutyrate (SAIB) finds its way into the world of pharmaceuticals as a stabilizer for oral suspensions and emulsions. The stakes are high—patients rely on consistent dosing and safety. If an excipient slips below standard, the whole batch can set off alarms in QC labs. My experience working with pharma-grade ingredients taught me to respect the difference between food- and pharma-grade status. Specifications aren’t just paperwork; they build real trust between chemist, regulator, and consumer.
Official monographs like those in the United States Pharmacopeia (USP) shape the benchmarks for pharmaceutical excipients. For SAIB, the USP and the European Pharmacopoeia spell out strict requirements. Clear, colorless to nearly colorless viscous liquid—no one wants to see opaque or yellow-tinted SAIB. Viscosity usually ranges between 200 and 430 centipoise at 25°C. This figure seems straightforward, but full compliance keeps downstream manufacturing processes on track, especially when mixing SAIB with other actives.
SAIB purity counts on several measurable figures. Most specs call for a content assay of at least 98.0% through gas chromatography. Water content remains tightly controlled, usually capped at 1%. Any more water risks microbial growth or instability—nobody enjoys failed stability data. Residual solvents—primarily acetone or isobutyric acid leftover from synthesis—must stay below controlled thresholds. Companies serious about GMP compliance send these excipients out for routine analysis, because solvent drift means rejections.
One of the biggest sticking points involves trace heavy metals. Pharma regulators require lead, arsenic, mercury, and similar contaminants to stay far below the safety line—often measured in parts per million. Lead, for example, sits below 0.5 ppm by many pharmacopeial standards. No shortcuts are acceptable here; even a fake sense of security can end in health risks. SAIB shouldn’t bring in any foreign taste, smell, or color. Organoleptic checks feel low-tech, but those who have run into off-odors know how quickly a new shipment can be rejected.
Sourcing pharma-grade SAIB means more than selecting the cheapest quote. Responsible companies audit their suppliers and check supply chain documentation, diving deep into Certificates of Analysis. Each batch brings its own report, and reputable manufacturers run high-performance liquid chromatography, GC, and titration methods. Regulators expect batch traceability, so working with well-documented ingredients cuts compliance risk sharply.
For those in formulation development, tighter control over excipient input pays dividends in product stability and predictable release profiles. Guideline adherence builds bigger bridges than trust alone. Auditing, third-party testing, and transparent communication with vendors all move projects forward smoothly. My experience has shown that finding trusted supply partners with documented compliance makes delivering safe, quality pharmaceuticals possible.
The pharma sector still faces new impurities and contaminants as raw materials evolve. Embracing better purification technology and fast analytical screening in-house helps spot trouble before it hits patients. Investing in equipment upgrades—automated titrators, modern spectrometry—may pull up cost in the short term but lowers product recalls and incident reports in the long run. For smaller companies, forming partnerships with technical consultants or contract labs delivers that same layer of protection and peace of mind.
Sucrose acetate isobutyrate, or SAIB, shows up as a clear, viscous liquid in labs and factories. It looks a lot like syrup, and its main job comes down to being a tasteless, nearly odorless carrier and stabilizer. In soft drinks, it holds flavors together, and in the pharmaceutical world, it works as a fixative, helping active ingredients stay suspended or stable in a mixture. The stuff gets made from simple building blocks: sucrose (common table sugar), acetic acid, and isobutyric acid. Chemicals get a bad rap, so folks want to know if SAIB is safe to swallow or inject.
Health authorities have studied SAIB in food and medicine since the 1970s. The Joint FAO/WHO Expert Committee on Food Additives (JECFA) reviewed studies on rats, rabbits, and dogs. At even high doses, animals showed no organ injury or strange growths. The U.S. Food and Drug Administration classified SAIB as “generally recognized as safe” (GRAS) for certain food uses back in the 1990s.
Pharmaceutical recipes get more complicated than colas. Medicines go directly into your bloodstream in some cases. Researchers have checked SAIB in injection forms and as part of slow-release capsules. In trials, SAIB stayed put, releasing medicine without breaking down or moving around the body. Doctors observed tested patients for allergic reactions or signs of toxic effects, but results came back clean. It helps that manufacturers must filter and purify every batch to keep out unreacted acids or impurities that could turn toxic in the body.
I’ve worked with pharmacists who run trials on slow-release injectable drugs, including depot steroids and vaccines. They look at every ingredient for unpredictable effects. SAIB gets picked because it does not leach or turn into something harmful inside the body. Still, it isn't wise to use SAIB where there’s no reason. Some compounds trigger rare allergies or interact with other components. Vigilance comes standard: a new application triggers rounds of animal, then human, safety trials before a drug makes it to patients.
Another real-world concern involves quality controls. SAIB needs to meet tight purity requirements in pharmaceutical settings. Producers have to keep tabs on each chemical input and document their processes. The FDA and similar watchdogs check that the SAIB in pharma settings matches those safety standards every time. That oversight matters because shortcuts in purification could let in leftover acids or bacterial spores.
The pharmaceutical industry always searches for safer, more precise carrier options. For some uses, natural gums, cellulose derivatives, or synthetic polyesters play the same roles. Science does not stand still. Drug developers may switch to another excipient if a safer, more biodegradable material appears. Some scientists push toward plant-derived options that break down faster, limiting environmental footprints.
Clear safety records and transparency help clinicians and patients trust their medications. No excipient, SAIB included, escapes scrutiny. People ask good questions about what goes in their bodies, and rightfully so. Long-term surveillance systems watch for problems, and doctors get alerts if patterns of side effects pop up. In nearly fifty years of food and medical research, using SAIB at controlled doses, in well-made formulations, hasn’t turned up major red flags.
Sucrose Acetate Isobutyrate, often called SAI in the beverage and food industry, pops up in soft drinks and flavored waters to help keep things from separating. It’s a tough, oily liquid that doesn’t look intimidating, but proper storage and handling make all the difference. People who deal with SAI in warehouses or production plants know that cutting corners with it invites trouble, from ruined batches to safety issues. Mistakes can mean money wasted and, more importantly, risking people’s health.
Every bottle or drum of SAI carries a shelf life, but those numbers don’t hold up if the product sits in heat or sunlight. I’ve seen workplaces lose whole shipments because a loading dock got too warm over the weekend. SAI does best in a cool, dry spot, shielded from direct light and temperature swings. Even a small temperature rise can cause thickening or discoloration, making it useless in production.
Container choice matters here. Metal drums with tight closures stand up best—not just against leaks, but also in reducing chances of air or moisture sneaking in. When SAI draws in water from humid air, it can cloud up or even start breaking down. Always keep containers sealed tight after each use, and always check gaskets and lids. Forgetting this step often means dealing with sticky messes the next day.
On the production floor, no day goes wrong faster than one with a spill or splash of SAI. Gloves and safety glasses stay on all shift, since oil-based chemicals like these slip across skin or clothing in no time. I’ve seen workers regret picking up leaky canisters bare-handed, learning quickly that cleanup is tougher than prevention.
Equipment used for SAI—like pumps and hoses—benefits from regular, thorough cleaning. Residual product can gum up lines or contaminate the next batch. In shared facilities, using separate tools for SAI prevents unwanted mixing. Good training helps here, too. The workers who get regular refreshers on chemical safety tend to spot problems before they spiral.
While SAI doesn’t ignite easily under normal circumstances, it’s still a flammable liquid. Storing it far from open flames, sparks, and hot machinery is just common sense. Most workplaces keep the fire extinguisher class B within arm’s reach and make sure flammable material signage is clear. In crowded spaces, clear labeling keeps everyone on the same page, especially during rushes when mistakes multiply.
Spills and leaks never go away on their own. SAI can travel with water, and it sticks to surfaces. Prompt cleanup, usually with absorbent pads and proper disposal containers, keeps it out of drains—avoiding local water contamination. Long-term, this attention keeps the workspace safe and keeps inspectors and local authorities off your back.
Good record keeping goes a long way. Track batch numbers, shelf life dates, and storage conditions, not just because regulations say so, but because it lets you spot slow leaks or off-spec material before anyone pours it into the mix. Some companies set up automatic monitoring for temperature and humidity in their storage rooms, which can pay for itself by saving a single lost drum.
In the end, treating SAI with respect—clean hands, proper storage, sound habits—protects the business and everyone involved. It’s not just about checking a box for compliance. It’s about doing the job right, every time.
Sucrose Acetate Isobutyrate, often abbreviated as SAI or SAIB, usually pops up in the pharmaceutical world as an excipient or stabilizer. It helps dissolve compounds that otherwise don’t play well with water, which is handy when manufacturers develop liquid medicines or controlled-release tablets. Sitting on a shelf in a warehouse or a lab, SAI by itself looks fairly ordinary—a thick, clear, viscous liquid. Yet, once it finds its way into a tablet or suspension, regulators take a much closer look at its safety and quality.
SAIB that appears in drug products must follow strict quality guidelines. The “BP,” “EP,” and “USP” tags reference three respected pharmacopeias: the British Pharmacopoeia, European Pharmacopoeia, and United States Pharmacopeia. Each of these sets tough quality standards for pharmaceutical ingredients.
If a manufacturer claims their SAIB meets BP, EP, or USP, they’re saying it passed heavy testing for purity, composition, and absence of hazardous contaminants. Regulators in the U.S. (the FDA), Europe (the EMA), and the UK expect pharma-grade excipients like SAIB to be produced in facilities that meet Good Manufacturing Practices (GMP). GMP isn’t a suggestion—it’s a requirement, verified through site inspections, paperwork, batch records, and regular audits. I’ve seen how a single missing signature or a deviation from a process can throw an entire shipment into question, and regulators do not let these things slip.
The U.S. Food and Drug Administration doesn't issue a “certificate” for every lot of excipient, but it demands that the company hold documentation proving compliance. In Europe, the EMA and national agencies apply similar scrutiny. Manufacturers may secure Certificates of Analysis (CoA) for lots, or Certificates of Suitability (CEP) from the EDQM, showing that the excipient meets monograph standards. Without those certificates, a drug containing that excipient won’t make it past a regulatory gatekeeper.
You can look up SAIB in the latest USP, BP, or EP volumes and see that each has a published monograph detailing exactly how the substance should perform on impurity screens, physical tests, and other quality checks. If a batch misses the mark, it can’t appear in pharmaceutical products bound for regulated markets.
Pharmaceutical companies collect stacks of safety data as part of their new drug applications. For novel excipients, companies sometimes need to file an independent data package with the FDA. SAIB isn’t new: it’s been used as a flavor stabilizer and excipient for decades, so most regulatory agencies recognize it for certain uses. Still, every lot and use case receives fresh scrutiny because excipient quality shapes patient safety.
There’s always room for improvement in how excipient suppliers and drug manufacturers work together. I’ve watched how digital supply chain tracking and clear data-sharing builds trust. If I were to recommend a direction, traceability tools and transparent records would help regulators, producers, and patients feel confident about the safety of every bottle and blister pack. It gives peace of mind, and it’s just common sense.
| Names | |
| Preferred IUPAC name | 1,2,3,3',4,4',6,6'-Octa-O-acetyl-5,5',6,6'-tetraisobutyryl-β-D-fructofuranosyl-α-D-glucopyranoside |
| Other names |
SAIB Sucrose acetate isobutyrate Sucrose acetoisobutyrate |
| Pronunciation | /ˈsuːk.roʊs ˌæs.ɪˈteɪt ˌaɪ.səˈbjuː.tɪ.rət biː piː iː piː juː ɛs piː ˈfɑːr.mə ɡreɪd/ |
| Identifiers | |
| CAS Number | 126-13-6 |
| Beilstein Reference | 1721108 |
| ChEBI | CHEBI:8997 |
| ChEMBL | CHEMBL2108777 |
| ChemSpider | 121474 |
| DrugBank | DB11434 |
| ECHA InfoCard | ECHA InfoCard: 100.014.319 |
| EC Number | EC 249-018-7 |
| Gmelin Reference | 7597 |
| KEGG | C01906 |
| MeSH | D013424 |
| PubChem CID | 16131517 |
| RTECS number | WNK748TCQ1 |
| UNII | 67BEK8S43G |
| UN number | Not regulated |
| Properties | |
| Chemical formula | C40H62O19 |
| Molar mass | 846.97 g/mol |
| Appearance | Clear, colorless to pale yellow, viscous liquid |
| Odor | Odorless |
| Density | 1.146 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | -2.7 |
| Vapor pressure | Vapor pressure: <0.1 hPa (20°C) |
| Acidity (pKa) | 12.1 |
| Basicity (pKb) | 14 |
| Magnetic susceptibility (χ) | -7.4×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.44 – 1.49 |
| Viscosity | 400 cP |
| Dipole moment | 2.3 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 900 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -1872 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -8370 kJ/mol |
| Pharmacology | |
| ATC code | A16AX53 |
| Hazards | |
| Main hazards | May cause respiratory irritation. Causes serious eye irritation. May cause skin irritation. |
| GHS labelling | GHS labelling for Sucrose Acetate Isobutyrate: "GHS07, Warning, H317: May cause an allergic skin reaction, P280, P302+P352, P333+P313 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | Not a hazardous substance or mixture. |
| Precautionary statements | P264, P270, P273, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | Health: 1, Flammability: 1, Instability: 0, Special: - |
| Flash point | **220°C** |
| Autoignition temperature | 420 °C (788 °F; 693 K) |
| LD50 (median dose) | LD50 (median dose): 25 g/kg (rat, oral) |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 25 mg/kg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Sucrose Sucrose octaacetate Sucrose benzoate Sucrose polyesters Cellulose acetate Isopropyl acetate Triacetin Acetylated monoglycerides |
Chengguan District, Lanzhou, Gansu, China
